Skip to main navigation menu Skip to main content Skip to site footer
Español (España) | English
Editorial
Revistas / Journals
Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home
Issue
Current Issue Previous Issues Thematic issues
About
About the Journal Editorial Team Privacy Statement Contact
Author Guidelines
Guidelines for authors Peer Review Process Open Access Policy and Copyright Digital preservation policy Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
×
Español (España) | English
Editorial

Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home

Current Issue Previous Issues Thematic issues

About the Journal Editorial Team Privacy Statement Contact

Guidelines for authors Peer Review Process Open Access Policy and Copyright Digital preservation policy Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
Original
Published: 2024-06-15
DOI: https://doi.org/10.56294/sctconf2024795

Review of the Use of Antisense Oligonucleotides as Therapy for Huntington's Disease

By
Ariel Solis-Chiriboga ,
Ariel Solis-Chiriboga

Universidad Técnica de Ambato. Ambato, Ecuador

Search this author on:

PubMed | Google Scholar
Alberto Bustillos ,
Alberto Bustillos

Universidad Técnica de Ambato. Facultad de Ciencias de la Salud, Carrera de Medicina, Ambato, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Huntington's disease is a neurodegenerative disorder characterized by the progressive degeneration of nerve cells in the brain, and whose current treatment focuses on the control of symptoms, which is why in recent years several therapies have been evaluated, including Antisense oligonucleotides a promising strategy, thanks to their ability to modulate the expression of the mutated huntingtin protein.
Methods:
A bibliographic search was carried out using the PRISMA methodology in databases such as PubMed, limited to documents in English published during the last 5 years, using keywords such as "Huntington's Disease", "Antisense Oligonucleotides", "Treatment" “Tominersen”, selecting only documents such as original articles, bibliographic reviews and clinical trial reports related to the use of Antisense Oligonucleotides as therapy for Huntington's Disease.
Results:
150 articles were collected and analyzed, of which 30 documents were excluded due to their age and 40 due to lack of access and quality of information, leaving a total of 80 articles to which inclusion criteria were applied, selecting 25 articles for completion. of this literature review on the use of antisense oligonucleotides in Huntington's disease
Conclusion: Antisense oligonucleotides show great therapeutic potential for Huntington's disease by directly attacking the underlying cause of the disease, mutated huntingtin. However, significant challenges still remain, which is why better research is needed to ensure efficacy. and safety of this therapy in the long term.

Keywords:

Antisense oligonucleotides,
Huntington's disease,
Mutated huntingtin,
Wild-type huntingtin,
Modulation,
clinical trials,

How to Cite

1.
Solis-Chiriboga A, Bustillos A. Review of the Use of Antisense Oligonucleotides as Therapy for Huntington’s Disease. Salud, Ciencia y Tecnología - Serie de Conferencias [Internet]. 2024 Jun. 15 [cited 2024 Jul. 1];3:795. Available from: https://conferencias.saludcyt.ar/index.php/sctconf/article/view/795

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

Vol. 3 (2024)
See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.